Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836880 monotherapy and combination with BI 754091 in Japanese patients with advanced solid tumors
NCT03972150Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2019
- Primary completion
- Oct 2020
- Modality
- Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 836880 in Neoplasm (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Phase 2 Dose at 21 days and 1 more. Started Jun 2019; status: completed.
02
Drugs
BI 836880
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT03972150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03972150.